Merck KGaA:Merck KGaA Receives CHMP Opinion on Erbitux for Lung Cancer

Merck KGaA / Regulatory Admission

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Darmstadt, Germany, July 23, 2009 - The Committee for Medicinal Products
for Human Use (CHMP), the scientific committee of the European Medicines
Agency (EMEA), has today adopted a negative opinion for the use of
Erbitux(R) (cetuximab) in combination with platinum-based chemotherapy for
the treatment of patients with epidermal growth factor receptor
(EGFR)-expressing, advanced or metastatic non-small cell lung cancer
(NSCLC). Merck is evaluating potential appeal options requesting that the
CHMP re-examine data demonstrating clinical relevant benefits to
patients.

Steffen Müller
+49 6151 72-2386


23.07.2009  Financial News transmitted by DGAP
----------------------------------------------------------------------
 
Language:     English
Issuer:       Merck KGaA
              Frankfurter Str. 250
              64293 Darmstadt
              Deutschland
Phone:        +49 (0)6151 72 62 95
Fax:          +49 (0)6151 72 31 64
E-mail:       investor.relations@merck.de
Internet:     www.merck.de
ISIN:         DE0006599905
WKN:          659990
Indices:      DAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, München, Hannover, Düsseldorf, Hamburg,
              Stuttgart; Terminbörse EUREX; Foreign Exchange(s) London,
              SWX
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------